The ADC Cytotoxic Payloads / Warheads market is anticipated to grow at a CAGR of 12.4% till 2030, claims Roots Analysis With six approved drugs, namely POLIVY™, LUMOXITI™, BESPONSA®, MYLOTARG™, KADCYLA®, ADCETRIS® and over 300 drugs underdevelopment, antibody drug conjugates (ADCs) have emerged as a promising class of targeted therapies for various disease indications. For additional details, please visit https://www.rootsanalysis.com/reports/adc-cytotoxic-payloads-market.html